Literature DB >> 22293266

Interobserver reproducibility of Gleason grading of prostatic adenocarcinoma among general pathologists.

R V Singh1, S R Agashe, A V Gosavi, K R Sulhyan.   

Abstract

CONTEXT: Gleason grade is the most widely used grading system for prostatic carcinoma and is recommended by World Health Organization. It is essential that there should be good interobserver reproducibility of this grading system as it has important implications in patient management. AIM: To assess interobserver reproducibility of Gleason grading of prostatic adenocarcinoma.
DESIGN: A total of 20 cases of prostatic adenocarcinoma were scored using Gleason grade by 21 general pathologists. The scores were then compared using κ-coefficient and consensus score.
RESULTS: For Gleason score groups (2-4, 5-6, 7 and 8-10) overall agreement with consensus score was 68%. Exact agreement for Gleason scores with consensus score was 43.3% and 92.3% within ±1 of the consensus score. κ coefficient for primary grade ranged from -0.32 to 0.92 with 60% of the readings in fair to moderate agreement range; and for secondary grade κ ranged from -0.30 to 0.62 with 78% of the readings in slight to fair agreement range. Kappa for Gleason scores ranged from -0.13 to 0.55 with 80% of the readings in slight to fair agreement range; and for Gleason score groups κ ranged from -0.11 to 0.82 with 68.5% of the readings in fair to moderate agreement range.
CONCLUSIONS: In our study interobserver reproducibility of Gleason scores among general pathologists was at lower level and it highlights the need to improve the observer reproducibility by continuous educational sessions and taking second opinion in cases where grade could significantly influence management.

Entities:  

Mesh:

Year:  2011        PMID: 22293266     DOI: 10.4103/0019-509X.92277

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  9 in total

1.  Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology.

Authors:  Jeong Hyeon Lee; Seok Ho Kang; Tae Il Noh; Ji Sung Shim; Sung Gu Kang; Jun Cheon; Jeong Gu Lee
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

2.  Gleason’s Grading of Prostatic Adenocarcinoma: Inter-Observer Variation Among Seven Pathologists at a Tertiary Care Center in Oman

Authors:  Asim Qureshi; Ritu Lakhtakia; Maiya AL Bahri; Ibrahim Al Haddabi; Anna Saparamadu; Asem Shalaby; Marwa Al Riyami; Gauhar Rizvi
Journal:  Asian Pac J Cancer Prev       Date:  2016-11-01

3.  Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer.

Authors:  Stefan Steurer; Benjamin Hager; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Sarah Minner; Till S Clauditz; Claudia Hube-Magg; Andreas M Luebke; Ronald Simon; Jakob R Izbicki; Eike Burandt; Guido Sauter; Christoph Fraune; Sören Weidemann; Thorsten Schlomm; Hans Heinzer; Alexander Haese; Markus Graefen; Hartwig Huland; Asmus Heumann
Journal:  Aging (Albany NY)       Date:  2019-09-25       Impact factor: 5.682

4.  High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.

Authors:  Sören A Weidemann; Charlotte Sauer; Andreas M Luebke; Christina Möller-Koop; Stefan Steurer; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Till S Clauditz; Ronald Simon; Guido Sauter; Cosima Göbel; Patrick Lebok; David Dum; Christoph Fraune; Simon Kind; Sarah Minner; Jakob Izbicki; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Eike Burandt; Alexander Haese; Markus Graefen; Asmus Heumann
Journal:  BMC Cancer       Date:  2019-10-12       Impact factor: 4.430

Review 5.  Translational AI and Deep Learning in Diagnostic Pathology.

Authors:  Ahmed Serag; Adrian Ion-Margineanu; Hammad Qureshi; Ryan McMillan; Marie-Judith Saint Martin; Jim Diamond; Paul O'Reilly; Peter Hamilton
Journal:  Front Med (Lausanne)       Date:  2019-10-01

Review 6.  A narrative review of digital pathology and artificial intelligence: focusing on lung cancer.

Authors:  Taro Sakamoto; Tomoi Furukawa; Kris Lami; Hoa Hoang Ngoc Pham; Wataru Uegami; Kishio Kuroda; Masataka Kawai; Hidenori Sakanashi; Lee Alex Donald Cooper; Andrey Bychkov; Junya Fukuoka
Journal:  Transl Lung Cancer Res       Date:  2020-10

7.  Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer.

Authors:  Renata Zelic; Francesca Giunchi; Luca Lianas; Cecilia Mascia; Gianluigi Zanetti; Ove Andrén; Jonna Fridfeldt; Jessica Carlsson; Sabina Davidsson; Luca Molinaro; Per Henrik Vincent; Lorenzo Richiardi; Olof Akre; Michelangelo Fiorentino; Andreas Pettersson
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

8.  Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer.

Authors:  Morton Freytag; Martina Kluth; Elena Bady; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Hans Heinzer; Doris Höflmayer; Sören Weidemann; Ria Uhlig; Hartwig Huland; Markus Graefen; Christian Bernreuther; Corinna Wittmer; Maria Christina Tsourlakis; Sarah Minner; David Dum; Andrea Hinsch; Andreas M Luebke; Ronald Simon; Guido Sauter; Thorsten Schlomm; Katharina Möller
Journal:  BMC Cancer       Date:  2020-12-18       Impact factor: 4.430

9.  Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.

Authors:  Andreas Marx; Andreas M Luebke; Till S Clauditz; Stefan Steurer; Christoph Fraune; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Christina Möller-Koop; Ronald Simon; Guido Sauter; Cosima Göbel; Patrick Lebok; David Dum; Simon Kind; Sarah Minner; Jakob Izbicki; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Eike Burandt; Alexander Haese; Markus Graefen; Jan Meiners
Journal:  Dis Markers       Date:  2020-04-25       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.